Avant Technologies Enters Longevity Biotech with Klothonova Joint Venture

Avant Technologies, Inc. has formed a joint venture with Singapore-based Austrianova to establish Klothonova, Inc., focusing on pioneering cell-based therapies. Announced in a press release, this partnership aims to leverage Austrianova's proprietary cell-encapsulation technology to develop treatments targeting Alzheimer's, heart disease, cancer, and other age-related conditions.

The joint venture will utilize encapsulated Klotho-producing cells, a protein linked to longevity, to address these therapeutic areas. Research indicates that higher levels of Klotho correlate with increased lifespan and improved cognitive, cardiovascular, and kidney functions. Avant Technologies provides capital and operational resources, while Austrianova contributes its expertise in cell biology and manufacturing.

This strategic move positions Avant Technologies within the rapidly expanding longevity biotechnology sector, with Klothonova's treatments advancing towards clinical validation and commercialization globally.